Cereno Scientific – increased international activity and exposure

15 October, 2019

Thrombosis is the most common cause of death the world over, whilst heart attack and stroke are the most common thrombosis-related complications. Furthermore, today’s thrombosis-preventative treatments increase the risk for serious bleeding. This has opened the door for brand new treatment concepts such as CS1, Cereno Scientific’s primary drug candidate that strengthens the body’s natural defences against thrombosis whilst reducing the risk of bleeding.

Read the full article on BioStock here.


3rd annual Anti-Fibrotic Drug Development Summit (AFDD) 2019-11-18 - 2019-11-20

16th Global Cardiovascular Clinical Trialists Forum 2019-12-05 - 2019-12-07

LeadingBiotech: East/West CEO 2020-01-11 - 2020-01-12

Biotech Showcase™ 2020 2020-01-13 - 2020-01-15

More about us...

Subscribe for corporate news

Follow us on LinkedIn

Follow us on Twitter

Privacy policy

We are proud supporters of World Thrombosis Day. Read more